Charles River Laboratories International (NYSE:CRL) Releases FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 9.100-9.600 for the period, compared to the consensus estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion. Charles River Laboratories International also updated its FY25 guidance to $9.10-$9.60 EPS.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CRL. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. CLSA cut shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a research report on Monday, November 18th. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday. Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Finally, UBS Group restated a "neutral" rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average price target of $195.71.

Charles River Laboratories International Trading Up 0.5 %

Charles River Laboratories International stock traded up $0.86 during trading hours on Friday, reaching $163.11. 1,211,286 shares of the company's stock were exchanged, compared to its average volume of 1,047,886. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm's 50 day simple moving average is $173.39 and its 200 day simple moving average is $188.81. The firm has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.46 EPS. Research analysts predict that Charles River Laboratories International will post 9.41 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).